Loxo Oncology reports plans to conduct public offering of common stock

Bookrunners Citigroup and Cowen conduct financing; Stifel will assist

By Devika Patel

Knoxville, Tenn., May 11 – Loxo Oncology, Inc. said it will sell price a public sale of common stock with a 30-day greenshoe.

Citigroup and Cowen and Co. are the bookrunners. Stifel is the joint lead manager.

Proceeds will be used for general corporate purposes, including research and development, working capital, acquisitions and investments.

The Stamford, Conn., company develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.